Sanofi
venglustat
type 3 Gaucher disease
Countdown
141days
FDA decision · Nov 25, 2026
What's at stake
The FDA's approval decision on venglustat for type 3 Gaucher disease is due Nov 25, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 12h ago
“The target action date for the FDA decision is November 25, 2026.”